Travera
Revolutionizing Cancer Therapy Guidance.
Revolutionizing Cancer Therapy Guidance.
Travera, with the slogan "Revolutionizing Cancer Therapy Guidance", was founded in 2017 and is headquartered in the United States. The company has received non-equity assistance investment from MedTech Innovator as of 06 June 2023. Travera stands out in the biotechnology and health care industries by utilizing a breakthrough measurement tool developed at MIT to directly measure the effectiveness of cancer drugs for individual patients before the drugs are administered. The company offers CLIA certified Rapid Therapy Guidance Tests for all major cancers and over 100 FDA-approved cancer drugs, providing results in just two days. With its innovative approach, Travera is poised to significantly impact the field of cancer therapy by providing personalized drug effectiveness assessments. This pioneering technology has the potential to enhance patient care and treatment outcomes in the fight against cancer.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
06 Jun 2023 |
| Series A | $4.00M | - | 13 Jul 2021 | |
| Grant | $1.00M | 1 |
|
11 Sep 2020 |
| Grant | $225.00K | 1 |
|
01 Feb 2019 |
| Venture Round | $8.41M | - | 15 Jun 2018 |
No recent news or press coverage available for Travera.
We care about your data, and we'd love to use cookies make your experience better.
